Evidence map›Paper›PMID 42788180›Full record

ArticleWorld journal of nuclear medicine2026

Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.

Cihan Şin, Burcu Esen Akkaş, Özge Vural Topuz, Özgür Omak, Enes M Kaya, Harun Özdemir, Begüm Çalım Gürbüz, Halil L Canat, Abdulmuttalip Şimşek, Meryem Kaya

Abstract read
In one paragraph

Article in World journal of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cihan ŞinDepartment of Nuclear Medicine, University of Health Sciences, Bağcılar Training and Research Hospital, Istanbul, Türkiye.ORCID 0000-0001-5293-6407
Burcu Esen AkkaşDepartment of Nuclear Medicine, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
Özge Vural TopuzDepartment of Nuclear Medicine, Acıbadem Mehmet Ali Aydınlar University, Acıbadem Maslak Hospital, Istanbul, Türkiye.
Özgür OmakDepartment of Nuclear Medicine, Hatay Training and Research Hospital, Antakya, Hatay, Türkiye.
Enes M KayaDepartment of Nuclear Medicine, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
Harun ÖzdemirDepartment of Urology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
Begüm Çalım GürbüzDepartment of Pathology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
Halil L CanatDepartment of Urology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.
Abdulmuttalip ŞimşekDepartment of Urology, Memorial Bahçelievler Hospital, Istanbul, Türkiye.
Meryem KayaDepartment of Nuclear Medicine, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to assess the diagnostic performance of diuretic-enhanced dual-phase F-18 FDG PET/CT in detecting muscle invasion in bladder cancer (BC) and to evaluate the predictive role of metabolic and volumetric PET parameters. Methods: A total of 105 patients (85 males, 20 females; mean age: 67.8 years) with suspected BC underwent F-18 FDG PET/CT for initial staging. Routine and delayed pelvic imaging was performed after intravenous furosemide. Metabolic and volumetric parameters, including SUV Results: Distant metastases were detected in 30 patients (28.5%), which directly influenced treatment decisions. In the TUR-B cohort ( Conclusion: Diuretic-enhanced dual-phase F-18 FDG PET/CT provides clinically valuable information for the assessment of detrusor muscle invasion and the differentiation of bladder lesions. Quantitative volumetric and metabolic parameters may serve as surrogate biomarkers, supporting preoperative staging and contributing to more precise, personalized treatment strategies for patients with BC.

Indexed as

bladder cancermetabolic tumor volumemuscle invasionpositron-emission tomographytotal lesion glycolysis

Identifiers

PMID42788180
PMCPMC13612137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.